CSL (CHIA:CSL) - Hisse Senedi Fiyatı, Haberler ve Analizler

CSL Stoklara Genel Bakış

CSL temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	5/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 29% daha düşük bir oranda işlem görüyor

Kazançların yılda 12.99% oranında artması öngörülüyor

Kazançlar geçen yıl 20.4% oranında arttı

Risk Analizi

Yüksek borç seviyesine sahip

CSL Limited Rakipler

Telix Pharmaceuticals

ASX:TLX

AU$8.0b

Clinuvel Pharmaceuticals

ASX:CUV

AU$653.8m

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$81.0b

Amgen

NasdaqGS:AMGN

US$150.5b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti CSL
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$285.81
52 Haftanın En Yüksek Seviyesi	AU$313.50
52 Haftanın En Düşük Seviyesi	AU$259.07
Beta	0.30
11 Aylık Değişim	-2.24%
3 Aylık Değişim	-6.95%
1 Yıllık Değişim	8.99%
33 Yıllık Değişim	-6.13%
5 Yıllık Değişim	3.16%
Halka arzdan bu yana değişim	315.54%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	CSL	AU Biotechs	AU Pazar
7D	4.6%	2.5%	0.8%
1Y	9.0%	11.2%	18.1%

Getiri vs. Endüstri: CSL geçen yıl % 11.2 oranında getiri sağlayan Australian Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: CSL geçen yıl % 18.1 oranında getiri sağlayan Australian Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is CSL's price volatile compared to industry and market?
CSL volatility
CSL Average Weekly Movement	2.2%
Biotechs Industry Average Movement	9.6%
Market Average Movement	8.4%
10% most volatile stocks in AU Market	17.0%
10% least volatile stocks in AU Market	3.2%

İstikrarlı Hisse Senedi Fiyatı: CSL son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: CSL 'nin haftalık oynaklığı ( 2% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1916	32,698	Paul McKenzie	www.csl.com.au

CSL Limited, Avustralya, Amerika Birleşik Devletleri, Almanya, Birleşik Krallık, İsviçre, Çin, Hong Kong ve uluslararası alanda biyofarmasötik ve aşı araştırmakta, geliştirmekte, üretmekte, pazarlamakta ve dağıtmaktadır. Şirket CSL Behring, CSL Seqirus ve CSL Vifor segmentleri aracılığıyla faaliyet göstermektedir. CSL Behring segmenti plazma ürünleri, gen terapileri ve rekombinantlar sunmaktadır.

CSL Limited Temel Bilgiler Özeti

CSL'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CSL temel i̇stati̇sti̇kler
Piyasa değeri	AU$138.09b
Kazançlar(TTM)	AU$4.07b
Gelir(TTM)	AU$22.78b

34.0x

F/K Oranı

6.1x

P/S Oranı

CSL aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CSL gelir tablosu (TTM)
Gelir	US$14.80b
Gelir Maliyeti	US$7.10b
Brüt Kâr	US$7.71b
Diğer Giderler	US$5.06b
Kazançlar	US$2.64b

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Feb 10, 2025

Hisse başına kazanç (EPS)	5.46
Brüt Marj	52.06%
Net Kâr Marjı	17.85%
Borç/Özkaynak Oranı	54.2%

CSL uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

1.4%

Mevcut Temettü Verimi

48%

Ödeme Oranı

CSL Stoklara Genel Bakış

Ödüller

Risk Analizi

CSL Limited Rakipler

ASX:TLX

AU$8.0b

ASX:CUV

AU$653.8m

NasdaqGS:REGN

US$81.0b

NasdaqGS:AMGN

US$150.5b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

MD, CEO & Executive Director recently sold AU$1.1m worth of stock

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

Upcoming dividend of US$1.45 per share

Final dividend of US$1.45 announced

Full year 2024 earnings released: EPS: US$5.47 (vs US$4.55 in FY 2023)

Recent updates

MD, CEO & Executive Director recently sold AU$1.1m worth of stock

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

Upcoming dividend of US$1.45 per share

Final dividend of US$1.45 announced

Full year 2024 earnings released: EPS: US$5.47 (vs US$4.55 in FY 2023)

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Now 21% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings released: EPS: US$3.94 (vs US$3.37 in 1H 2023)

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings released: EPS: US$4.55 (vs US$4.81 in FY 2022)

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

Upcoming dividend of US$1.07 per share at 1.1% yield

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

Independent Non Executive Director recently bought AU$74k worth of stock

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Non-Independent Non-Executive Director recently sold AU$6.4m worth of stock

Upcoming dividend of US$1.18 per share

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

Full year 2022 earnings released: EPS: US$4.81 (vs US$5.22 in FY 2021)

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

Now 20% undervalued

Now 21% undervalued after recent price drop

Upcoming dividend of US$1.04 per share

Independent Non-Executive Director recently bought AU$54k worth of stock

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited has completed a Follow-on Equity Offering in the amount of AUD 750.028364 million.

CSL Limited (ASX:CSL) entered into a definitive agreement to launch public tender offer to acquire Vifor Pharma AG (SWX:VIFN) from Patinex AG and other for CHF 10.9 billion.

Vifor Pharma and CSL Confirm Merger Talks

Centerview Reportedly Role in Vifor Sale